BioAge
@bioagelabs
Followers
5K
Following
804
Media
299
Statuses
853
BioAge is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases.
Richmond, CA
Joined August 2015
Today at Longevity Biotech 2025—part of Boston Longevity Week—BioAge co-founder and COO @eric_k_morgen, MD, will join a panel entitled "Shaping the Regulatory Roadmap for Longevity Drugs." The conversation will address one of our field's most pressing challenges: navigating
0
2
8
Today at the 2025 @agingbiomarkers conference at Harvard Medical School, BioAge CEO @kpfortney will share a talk entitled "Decoding Metabolic Aging: Data-Driven Paths from Human Cohorts to Biomarkers and Drug Targets." Dr. Fortney's presentation will highlight how BioAge's
0
2
8
WEBINAR: Today at 12 PM PT, BioAge CEO and co-founder @kpfortney will join experts from the academic, biotech, and public sectors in a panel discussion on the current state of existing and emerging drug interventions to extend healthspan. The event, which will be broadcast live,
0
1
5
Thanks to all who joined us for our fifth Boston longevity biotech mixer - a series of events that brings together the community of innovators in the Greater Boston area who are working to translate insights from aging biology into new medicines to treat disease and extend
0
0
7
At LSX World Congress USA in Boston next week, our CBO & Head of Brain Aging @PengLeong1 is looking forward to discussing how strategic partnerships accelerate innovation—and presenting BioAge's approach to enhancing incretin therapy through complementary oral mechanisms. •
0
0
3
"A lot of people already make it past the age of 100 and they're healthy. So why can't that be achievable for all of us?" - @kpfortney, CEO of @bioagelabs This vision has taken root across the investment community. A @WSJ analysis reports that over the past 25 years, over $12.5
2
1
10
Delighted to share that our study with @bioagelabs NLRP3 inhibitors is now online @JExpMed ! Together with @Geyer_lab @benedicte_py and @Innate_immuno we characterise BAL-0028 and BAL-0598. Excited to see the new NLRP3 biology they will reveal!
#NLRP3 is a target for anti-inflammatory therapies & can be inhibited by the tool compound MCC950. Wilhelmsen, @Rebecca_Coll et al. characterize new small-molecule inhibitors, BAL-0028 & BAL-0598, that have a distinct mechanism of action & binding site. https://t.co/w1xwgcU8wG
8
24
94
We’re pleased to announce our new publication today in Journal of Experimental Medicine describing the discovery and characterization of the novel class of NLRP3 inhibitors that includes BGE-102, a brain-penetrant, orally available small molecule that BioAge is initially
0
4
22
In the poster session at the 2025 @ARDD_Meeting , BioAge's Senior Director of Data Analytics Kia Winslow presented BioLens, our LLM-powered tool that transforms vast bodies of scientific literature into structured, analyzable datasets to accelerate aging biology and drug
3
0
9
At the 2025 @ARDD_Meeting , BioAge's SVP of Research @rmontonio presented our NLRP3 inflammasome inhibitor program, showcasing how structural biology and human longevity insights converge to create novel therapeutics. In his talk, Rusty described the discovery of structurally
0
1
8
Last week at @ARDD_Meeting, BioAge CEO @kpfortney joined distinguished representatives from biopharma to discuss how pharma-biotech partnerships are accelerating the translation of aging biology into therapies. Thank you to Lisa Melton, Senior News Editor at @NatureBiotech, for
0
3
11
We're excited to announce that we've dosed the first participant in our Phase 1 clinical trial of BGE-102, our novel brain-penetrant NLRP3 inhibitor being developed for metabolic diseases such as obesity. Key points: • First-in-human study evaluating safety, tolerability, and
globenewswire.com
First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential...
1
9
38
The @bioagepodcast features the people & companies advancing the science of human longevity and discovering drugs to extend healthspan. Our newest episode just dropped!
"Five scientists in a room don't make a company. Prolonging rodent lives doesn't make a company either." In our latest episode, Sergey Jakimov of LongeVC offers straight talk about what makes a longevity company investable. From his perspective as managing partner of one of
0
1
8
The @bioagepodcast features the people & companies advancing the science of human longevity and discovering drugs to extend healthspan. Our newest episode just dropped!
How can we translate cutting-edge geroscience into medicines that will benefit humanity? This week's special episode features a live panel from the 25th Bay Area Aging Meeting, where six leading voices across academia, industry, and publishing tackled the critical challenge of
0
1
8
Excited to share our new preprint on our research providing detailed structural insights into BioAge’s novel class of brain-penetrant NLRP3 inhibitors, targeting a core driver of metabolic aging. In this study, we identified a new binding pocket on NLRP3 and demonstrated how it
biorxiv.org
Low-grade inflammation is a hallmark of ageing and a key cause of age-related impairments and diseases[1][1]. The NOD-like receptor NLRP3 senses a variety of danger signals and environmental insults,...
0
5
22
At Discovery & Development Europe 2025 in Basel this week, our VP-Data Science Naisha Shah, PhD, showcased how human aging data can transform drug target discovery. In her talk "Targeting aging biology: exercise induced pathways for the treatment of neurodegenerative disease,"
0
1
0
Proud to share that BioAge presented some of our compelling new preclinical data on APJ agonism at the @AmDiabetesAssn's 85th Scientific Sessions this week. BioAge is advancing next-generation APJ agonists to translate this promising biology into new therapies for obesity and its
1
0
15
The future of drug discovery is rooted in human biology—starting with preclinical human models that boost translational success. At #BIO2025, BioAge CEO @kpfortney joined the panel “Replacing Guesswork with Data: How Preclinical Human Models Are Driving More Predictive Drug
1
0
6